MARKET NEWS

mCig Announces Topical Pain Relief Formulations
Melt Pharmaceuticals Initiates Clinical Development Program
Polyganics Initiates First-in-Human Trial of LIQOSEAL
Athenex Presents Encouraging Clinical Trial Efficacy & Safety Results
Velesco Pharma Expands, Acquires  New Research & cGMP Analytical Laboratory
CytomX Therapeutics Presents Clinical Data From Probody Platform

  FEATURED EDITORIAL

  COMPANY PROFILE

Founded in 1897, BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to healthcare. BD is a reliable partner that can provide expertise in highly specific fields to support your drug throughout its lifecycle, from development to launch and beyond. The company is committed to building partnerships with pharmaceutical and biotechnology companies and developing product solutions that meet their needs by leveraging our innovative technologies, extensive global manufacturing, and advanced technical, scientific, medical, and regulatory expertise. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award

A team of industry experts awarded Nemera’s electronic add-on for ophthalmic droppers with a prestigious CPhI Award for Best Drug Delivery Device in its category.

Alcami Helps Medicines Development for Global Health Secure FDA Approval

Alcami Helps Medicines Development for Global Health Secure FDA Approval

Alcami Corporation recently announced its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries.

Novel Oral Therapies Could Transform the Standard-of-Care for DME  & Lead to Preventative Treatment

Novel Oral Therapies Could Transform the Standard-of-Care for DME  & Lead to Preventative Treatment

Verseon, a technology-based pharmaceutical company, is presently developing multiple novel, small-molecule inhibitors of plasma kallikrein for the treatment of DME. Plasma kallikrein is a central mediator in the kallikrein-kinin system (KKS), a well-known pathway addressing an underlying cause of DME.

VistaGen Therapeutics Acquires Worldwide Rights to Develop & Commercialize First-in-Class Intranasally Administered Drug

VistaGen Therapeutics Acquires Worldwide Rights to Develop & Commercialize First-in-Class Intranasally Administered Drug

VistaGen Therapeutics Inc. recently announced it has exercised its option to acquire from Pherin Pharmaceuticals, Inc. the exclusive license for worldwide rights to develop and commercialize PH10, a first-in-class, intranasally administered neuroactive steroid (a pherine), with rapid-onset antidepressant effects for treatment of major depressive disorder (MDD) demonstrated in a Phase 2a study

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study

VBI Vaccines Inc. recently announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac, the company’s third-generation prophylactic hepatitis B vaccine.

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

Like all pharmaceuticals, ophthalmic preparations are subject to microbiological contamination. Both ophthalmic solutions used for diagnostic and therapeutic purposes have been found to be contaminated by pathogenic bacteria with reported rates as high as 70%, associated with severe ocular infections such as keratitis and endophthalmitis.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 7 – Formulation Development
November 14 – Prefilled Syringes